Diagnose multiple respiratory tract infections with the BD Veritor™ Plus System to help minimize their spread as well as reduce their duration.
Optional modules allow the BD Veritor™ Plus System to integrate seamlessly into your EMR/LIS and streamline your workflow to benefit your practice.
The BD Veritor™ Plus System is a versatile and efficient rapid diagnostic testing program with robust support, giving you the ability to provide reliable results and decide on a course of treatment for your patients quickly at the point of care, and in the environment that makes them most comfortable.
In acute care settings—where health complexities, rapid decision-making, and workflow systems converge—it becomes easy to appreciate the effortlessness with which the BD Veritor™ Plus System accommodates changes in workflow and capacity.
Point-of-care rapid diagnostic testing has become increasingly essential, and the BD Veritor™ Plus System can make a big difference. In-house respiratory tract infection testing with reliable, rapid results means staff is more prepared for rapid triage; able to detect and diagnose infections and even treat a patient in the same visit.
As a community organization, you have many priorities, but we know you have people to protect. You require flexibility, simplicity and reliability, so that those you serve and those who work for you can continue to enjoy life. With the BD Veritor™ Plus System, you can identify certain respiratory infections and then take steps to limit the spread of these respiratory infections throughout your organization and the community.
BD Veritor™ Plus System Overview Brochure
BD Veritor™ SARS-CoV-2 and Flu A+B Sell Sheet
BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 & Flu A+B Instructions for Use
BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 Instructions for Use
The BD Veritor™ Plus System enhances point-of-care testing for SARS-CoV-2,* Flu A+B, RSV, and Group A Strep assays, providing rapid diagnostic testing in a convenient, portable instrument.
* The BD Veritor™ System for Rapid Detection of SARS-CoV-2 is intended for the qualitative detection of SARS-CoV-2 nucleocapsid antigens in direct anterior nasal swabs from individuals who are either suspected of COVID-19 by their health care provider within the first five days of the onset of symptoms, or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests.
This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories.
RSV=respiratory syncytial virus; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.
This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens.
This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated, or authorization is revoked sooner.
Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C §263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.